Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- PMID: 19211503
- DOI: 10.1093/annonc/mdn729
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
Comment in
-
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.Ann Oncol. 2009 May;20(5):966-7; author reply 967. doi: 10.1093/annonc/mdp201. Ann Oncol. 2009. PMID: 19403939 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
